Please login to the form below
HTA guidance from NICE, the SMC and the AWMSG
Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).
Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.
Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)
September 2018: Independent professional body guideline
Asthma (update)
September 2018: NICE Quality Standard
Depression in adults (update)
September 2018: NICE Quality Standard
Eating disorders
September 2018: NICE Quality Standard
Ovarian cancer (refresh)
September 2018: SIGN guidance
Renal replacement therapy
October 2018: NICE Clinical Guideline
Decision making and mental capacity
October 2018: NICE Social Care Guidance
Foetal alcohol spectrum disorder (update)
October 2018: SIGN guidance
Abdominal aortic aneurysm: diagnosis and management
November 2018: NICE Clinical Guideline
Contraceptive choices for women who are obese/overweight
November 2018: Independent professional body guideline
NICE turns down bluebird bio’s gene therapy Zynteglo
11 Feb 2021
NICE did add, however, that these trials suggest that eventually certain TDT patients treated with Zynteglo may no longer require blood transfusion or may require them less often. ... NICE’s draft guidance of Zynteglo is open for consultation until 4
Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis
22 Jan 2021
Care Excellence (NICE). ... This is a landmark decision from NICE and represents a pivotal moment for the treatment of RA,” said James Galloway, consultant rheumatologist at King’s College London Hospital.
Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
20 Nov 2020
Securing NHS reimbursement is the culmination of collaborative discussions that we have been having with NICE and NHS England since the end of last year,” said Laura McMullin, general manager UK ... We worked closely with clinicians to submit evidence
NICE launches consultation on its methods of drug evaluation
9 Nov 2020
In addition, new cancer treatments can be approved via NICE’s Cancer Drugs Fund (CDF) which was introduced in 2016. ... NICE said there is also a ‘case for change’ regarding how it values costs and health effects for health technologies.
Novartis’ MS therapy Mayzent approved by NICE
16 Oct 2020
Mayzent (siponimod), a sphinogosine 1-phosphate receptor modulator, is the first oral disease-modifying treatment recommended by both NICE and the Scottish Medicines Consortium (SMC) for SPMS with active disease. ... According to NICE, around 11, 000
MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.
To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
SENIOR MEDICAL WRITER
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- Novavax to provide 1.1 billon COVID-19 vaccine doses to COVAX
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- The Good Ideas Group - Showreel
- J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing
- FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD
- Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US
- bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
- WHO agrees to no-fault compensation for rare serious side effects from COVAX-distributed vaccines
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Quick links
Infographics
